Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 21Unknown 4Recruiting 2Active not recruiting 2Not yet recruiting 1No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 3Lymphoma, Mantle-Cell 2Lymphoma 2Recurrence 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

tislelizumab 2pembrolizumab 2fludarabine phosphate 2fludarabine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2sintilimab 1pegfilgrastim 1liposomal doxorubicin 1Vinorelbine 1Vinblastine 1Specimen Handling 1Radiotherapy 1Proton Therapy 1Neuropsychological Tests 1Gemcitabine 1Fluorodeoxyglucose F18 1Doxorubicin 1Dacarbazine 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Hodgkin Disease × Bendamustine Hydrochloride × Clear all
NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡